ScreenerHero

AIM AIM ImmunoTech Inc.

AMEX · US · Healthcare · Biotechnology · aimimmuno.com
0.1828USD+0.16%Mkt Cap: 7.29M $P/E: —

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap7.29M USD
Enterprise Value-487.31K USD
Revenue (TTM)95.00K USD
Gross Profit-40.00K USD
Net Income (TTM)-13.96M USD
Revenue/Share0.01 USD
Last Price0.1828 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.49
PEG0.71
EV/EBITDA0.04
EV/Revenue-5.13
P/S76.64
P/B0.68
EPS (TTM)-2.86
EPS (Forward)-0.37
52W Range
0.16621% of range2.890
52W High2.890 USD
52W Low0.1662 USD
Profitability
Gross Margin-45.45%
Oper. Margin-13511.54%
EBITDA Margin0.00%
Profit Margin-15861.36%
ROE142.68%
ROA-241.40%
Growth
Revenue Growth4.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.96M USD
CapEx (TTM)378.00K USD
FCF Margin-14800.53%
FCF Yield-192.80%
Net Debt-6.04M USD
Net Debt/EBITDA0.56
Balance Sheet
Debt/Equity-0.50
Current Ratio2.11
Quick Ratio2.02
Book Value/Sh0.27 USD
Cash/Share0.33 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1031:1000
Split DateFeb 10, 2026
Analyst Consensus
Rating—
Target (Mean)4.250 USD
Upside (mean)+2224.9%
Target Range1.500 USD – 7.000 USD
1.500+2224.9% to mean7.000
# Analysts2
Ownership
Shares Out.39.89M
Float27.64M
Insiders0.51%
Institutions2.88%
Short Interest
Short Ratio0.2d
Short % Float7.08%
Short % Out.7.06%
Shares Short2.77M
Short (prev mo.)691.53K
Technical
SMA 500.2300 (-20.5%)
SMA 2000.5848 (-68.7%)
Beta1.27
S&P 52W Chg16.45%
Avg Vol (30d)2.80M
Avg Vol (10d)1.31M
Technical Indicators
RSI (14)37.0
MACD-0.0208
MACD Signal-0.0217
MACD Hist.+0.0009
BB Upper0.2566 USD
BB Middle0.2060 USD
BB Lower0.1553 USD
BB Width49.15%
ATR (14)0.0171 USD
Vol Ratio (20d)0.15x